Tuhura Biosciences Inc (HURA) Stock Price, Quote & News

Company Profile

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to dev...

Industry: Biotechnology

Sector: Healthcare

Phone: 813 875 6600

Website: www.tuhurabio.com

Address:

10500 University Center Drive, Suite 110, Tampa, United States

tommyhoover64 Jul. 11 at 11:29 AM

$HURA headed back to pennyland, like clockwork. Money comes to die here

0 · Reply

Evey Jul. 4 at 4:22 AM

$HURA what's your thoughts on this next week? Hopefully the spike down before closing is due to long wkend

1 · Reply

cranio_verde Jul. 3 at 7:22 PM

$HURA

0 · Reply

Moonman321 Jul. 3 at 4:23 AM

$HURA heading to 4

0 · Reply

cranio_verde Jul. 2 at 11:23 AM

$HURA

1 · Reply

Evey Jul. 2 at 7:06 AM

$HURA spike to 2.78 AH.. are we looking at 3-4 today 👀

0 · Reply

TraderNice Jul. 1 at 5:52 PM

$HURA yesterday it was the merger, today is the Russell 2000 and Russell 3000…this is the catalyst today…buying shares and raising the price of the stock…it’s going to go up today.

0 · Reply

TraderNice Jul. 1 at 3:40 PM

$HURA The merger and being included in the Russell 2000 and 3000 is big and hopefully this can push it too at least 3.00

1 · Reply

Abo_Hamza Jul. 1 at 12:56 PM

$HURA

1 · Reply

TraderNice Jun. 30 at 4:17 PM

$HURA That tight consolidation just under VWAP could absolutely be the early stages of a bullish flag forming. The Flagpole it has the sharp move up from ~$2.00 to ~$2.22-$2.27 earlier today. The Flag, the sideways chop or slight downward drift just under VWAP - low volume, tight range VWAP Hovering? Price is hugging VWAP, not rejecting it …..that's constructive This pattern often signals that buyers are resting, not bailing, and if volume returns, it can lead to a breakout continuation.

0 · Reply

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

Jul 1, 2025, 8:50 AM EDT - 11 days ago

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 30, 2025, 8:50 AM EDT - 12 days ago

TuHURA Biosciences Completes Acquisition of Kineta

Jun 24, 2025, 8:00 AM EDT - 18 days ago

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

Jun 23, 2025, 5:00 PM EDT - 18 days ago

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

Jun 9, 2025, 8:00 AM EDT - 4 weeks ago

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

Jun 3, 2025, 9:58 AM EDT - 5 weeks ago

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

Jun 2, 2025, 8:03 AM EDT - 5 weeks ago

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

May 15, 2025, 4:10 PM EDT - 2 months ago

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 13, 2025, 8:00 AM EDT - 2 months ago

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

May 5, 2025, 8:00 AM EDT - 2 months ago

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

Apr 28, 2025, 8:00 AM EDT - 2 months ago

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 3 months ago

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

Apr 7, 2025, 8:24 AM EDT - 3 months ago

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

Apr 1, 2025, 8:00 AM EDT - 3 months ago

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Mar 11, 2025, 8:05 AM EDT - 4 months ago

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.

Mar 10, 2025, 9:00 AM EDT - 4 months ago

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

Feb 19, 2025, 9:00 AM EST - 5 months ago

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Dec 20, 2024, 10:18 AM EST - 7 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTS and HURA on Behalf of Shareholders

VTS

Dec 12, 2024, 8:45 AM EST - 7 months ago

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

Nov 25, 2024, 8:35 AM EST - 8 months ago

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

Oct 23, 2024, 8:30 AM EDT - 9 months ago

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Oct 22, 2024, 9:00 AM EDT - 9 months ago

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

Oct 17, 2024, 4:35 PM EDT - 9 months ago

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

Oct 16, 2024, 12:54 PM EDT - 9 months ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

Oct 16, 2024, 11:58 AM EDT - 9 months ago

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

Oct 15, 2024, 4:15 PM EDT - 9 months ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Oct 14, 2024, 8:30 AM EDT - 9 months ago

Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Oct 8, 2024, 7:00 AM EDT - 9 months ago

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

Sep 20, 2024, 9:25 AM EDT - 10 months ago

Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

Sep 18, 2024, 8:30 AM EDT - 10 months ago

Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences

Sep 11, 2024, 8:30 AM EDT - 10 months ago

Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study

Sep 9, 2024, 8:30 AM EDT - 10 months ago

Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.

Aug 19, 2024, 9:00 AM EDT - 11 months ago

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

Jul 8, 2024, 6:30 AM EDT - 1 year ago

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

Jul 1, 2024, 8:35 AM EDT - 1 year ago

Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones

Jun 3, 2024, 8:35 AM EDT - 1 year ago

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

May 14, 2024, 4:45 PM EDT - 1 year ago

Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results

Apr 5, 2024, 1:31 PM EDT - 1 year ago

KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

Mar 27, 2024, 9:00 AM EDT - 1 year ago

Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab

Feb 14, 2024, 4:07 PM EST - 1 year ago

Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update

Feb 12, 2024, 9:00 AM EST - 1 year ago

Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer

Jan 2, 2024, 7:06 AM EST - 1 year ago

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)

CORT MIST RPID

Dec 18, 2023, 7:39 AM EST - 1 year ago

Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)

DRRX

Dec 7, 2023, 9:00 AM EST - 1 year ago

Kintara Therapeutics Announces Review of Strategic Alternatives

Dec 5, 2023, 9:00 AM EST - 1 year ago

Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement

tommyhoover64 Jul. 11 at 11:29 AM

$HURA headed back to pennyland, like clockwork. Money comes to die here

0 · Reply

Evey Jul. 4 at 4:22 AM

$HURA what's your thoughts on this next week? Hopefully the spike down before closing is due to long wkend

1 · Reply

cranio_verde Jul. 3 at 7:22 PM

$HURA

0 · Reply

Moonman321 Jul. 3 at 4:23 AM

$HURA heading to 4

0 · Reply

cranio_verde Jul. 2 at 11:23 AM

$HURA

1 · Reply

Evey Jul. 2 at 7:06 AM

$HURA spike to 2.78 AH.. are we looking at 3-4 today 👀

0 · Reply

TraderNice Jul. 1 at 5:52 PM

$HURA yesterday it was the merger, today is the Russell 2000 and Russell 3000…this is the catalyst today…buying shares and raising the price of the stock…it’s going to go up today.

0 · Reply

TraderNice Jul. 1 at 3:40 PM

$HURA The merger and being included in the Russell 2000 and 3000 is big and hopefully this can push it too at least 3.00

1 · Reply

Abo_Hamza Jul. 1 at 12:56 PM

$HURA

1 · Reply

TraderNice Jun. 30 at 4:17 PM

0 · Reply

TraderNice Jun. 30 at 3:52 PM

$HURA interesting? I thought the stock would drop to 2.00 but it’s consolidating at the 2.27 area, if this continues and breakthrough the 2.27 area we should see higher highs and higher lows…but volume needs to continue to grow..we need to break the VWAP…big battle here

0 · Reply

TraderNice Jun. 30 at 2:26 PM

$HURA Great Catalyst, but people have to digest the little dilution and might drop a lot but it will reclaim the VWAP at 2.28 around midday and rally at power hour to the high 2’s

0 · Reply

Gsgsghshh Jun. 30 at 2:04 PM

$HURA

0 · Reply

TraderNice Jun. 30 at 1:32 PM

$HURA wow…uh?

0 · Reply

stonkmamma Jun. 30 at 12:54 PM

$HURA news! Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA's late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase 2 randomized trial involving VISTA inhibiting antibody in 2nd Half 2025 Completion of the acquisition unlocks the fourth tranche of funds from $12.5 million aggregate PIPE financing announced June 3, 2025 TAMPA, Fla., June 30, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the successful completion of the acquisition of Kineta, Inc. (OTCPK:KANT) ("Kineta")

0 · Reply

TraderNice Jun. 30 at 3:26 AM

$HURA People are concerned of the 200 million shares authorized? Listen! No S-1 filing, no dilution. Or at least, no new registered dilution. Let me clarify: The key idea is that dilution only occurs when new shares are actually issued, not just because they’re authorized. So, unless TuHURA does the following, offers those new shares to the public, issues shares through a private placement that’s later registered or registers existing shares for resale……then there’s no actual dilution happening yet.

0 · Reply

TraderNice Jun. 27 at 7:53 PM

$HURA Why did this sell off today? The increase of 200 million authorized Common Shares Stock scared people away and the stock just sold off. This is not dilution, the authorized shares is to expand the company.....no dilution. This is the company fault they should have sent out the S-1 today not this notification...Ugh! Where is my S-1!

0 · Reply

TraderNice Jun. 27 at 7:40 PM

$HURA Increase Authorized Common Shares Stock * **No Immediate Dilution:** This action does not immediately reduce the ownership percentage of existing shareholders. It merely grants the company the option to issue additional shares in the future. Potential for Future Dilution? If TuHURA chooses to issue more shares (for instance, through public offerings or employee stock plans), the ownership percentages of existing shareholders could potentially decrease. Sign of Growth Ambitions? Increasing the authorized shares is frequently indicative of a company’s intentions for growth, expansion, or substantial transactions.

0 · Reply

Nadz1 Jun. 27 at 6:03 PM

$HURA doubled up!

0 · Reply

TraderNice Jun. 27 at 1:33 AM

$HURA This stock needs the filing of S-1 to give guidance for the investors and then the file will move fast

0 · Reply

johnnybknows Jun. 26 at 8:25 PM

$HURA All this steady bs pumping will not keep this from dropping. Company is running out of cash fast. More dillution and a likely stock split by years end. Learn the facts before investing

0 · Reply

Nadz1 Jun. 26 at 8:14 PM

$HURA T212 showing @$2.25 thats cool..Ill place another order and accumulate more shares. 👍

0 · Reply

Market Cap	110.07M
Revenue (ttm)	0.00
Net Income (ttm)	-21.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	215,800
Avg Vol	263,926
Day's Range	N/A - N/A
Shares Out	43.68M
Stochastic %K	24%
Beta	0.17
Analysts	Strong Sell
Price Target	$11.25